#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    SAPHO syndrome Acute graft versus host disease in liver Metastatic gastric cancer Anal squamous cell carcinoma Stress cardiomyopathy Spinal cord injury Leukocyte adhesion deficiency Pleomorphic leiomyosarcoma Ovarian cancer stage IV Acromegaly Malignant peritoneal neoplasm Aspergillus infection General anaesthesia Transplant rejection Vascular malformation More trials…

    Learn about Rare Diseases

    Vascular malformation – Diagnostics Congenital generalised lipodystrophy Pemphigoid – Basic Information Mucous membrane pemphigoid – Treatment Usher’s syndrome – Diagnostics Sarcoma – Life with Disease Systemic mastocytosis – Life with Disease Arterial tortuosity syndrome – Trials in Disease Hepatic angiosarcoma – Life with Disease Turner’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cisplatin Landiolol Hydrochloride Tegoprubart Buprenorphine Fluvastatin Morf-057 Escitalopram Filgotinib Tezepelumab Pozelimab Odevixibat Ipatasertib DROSPIRENONE Pegfilgrastim Bidridistrogene Xeboparvovec Dnth103 Lysine Acetate Trastuzumab Deruxtecan Gentamicin Mometasone Furoate Monohydrate More therapies…

    Learn about Your Condition

    Short-bowel syndrome Immune-mediated enterocolitis Raynaud's phenomenon Spina bifida Mantle cell lymphoma recurrent Drug eruption Malignant neoplasm of choroid Facial paresis Migraine Renal cancer recurrent Neurofibromatosis Brain cancer metastatic Intestinal ischaemia Congenital aplastic anaemia Pneumonia chlamydial More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2hs Bazushgwh Dy Sgpasi Mcrqanvxhhy Bs 1gqn Mqaqixalxr 1uqfeh Fyarav

Want to learn more about this study or check if you can participate? Contact us.

  • Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer metastatic
    Investigated Drugs:
    • Pf-07220060 Monohydrate
    • Letrozole
    Belgium France Germany Italy Poland Slovakia +2

  • Study on the Effectiveness of Nivolumab, Ipilimumab, and Pazopanib in Patients with Advanced Rare Sarcomas

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Sarcoma
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    • Pazopanib
    France

  • Study on Isatuximab, Lenalidomide, and Dexamethasone for Elderly Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Dexamethasone
    • Isatuximab
    France

  • Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer metastatic
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Durvalumab
    • Fulvestrant
    • Goserelin Acetate
    Belgium France Spain

  • Study on Improving Survival in Acute Myeloid Leukemia for Adults Aged 18-60 Using Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Cytarabine
    • Venetoclax
    France

  • Study of Bintrafusp Alfa and Doxorubicin Hydrochloride for Adults with Advanced Soft-Tissue Sarcoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Soft tissue sarcoma
    Investigated Drugs:
    • Bintrafusp Alfa
    • Doxorubicin Hydrochloride
    France

  • Study of Atezolizumab Combined with Radiotherapy in Patients with Operable Soft Tissue Sarcomas

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Sarcoma
    Investigated Drugs:
    • Atezolizumab
    France

  • Study on Stopping and Restarting Acalabrutinib in Elderly Patients with Untreated Chronic Lymphocytic Leukemia (CLL)

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    France

  • Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Untreated Higher-Risk Myelodysplastic Syndromes Not Eligible for Transplant

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Azacitidine
    • Venetoclax
    France

  • Study of ODM-208 (opevesostat) safety and effectiveness in patients with metastatic castration-resistant prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Dobutamine Hydrochloride
    • Odm-208
    • Opevesostat
    Finland France
Previous Page
1 … 39 40 41 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!